前列腺癌患者中促性腺激素释放激素拮抗剂与激动剂心血管安全性的比较:真实世界证据研究的系统综述与Meta分析
该系统综述与Meta分析检索2008至2023年多个数据库,纳入10项真实世界证据研究,比较促性腺激素释放激素(GnRH)拮抗剂与激动剂在前列腺癌患者中的心血管安全性。主分析中3项中等偏倚风险研究显示,地加瑞克与主要不良心血管事件(MACE)风险升高相关(汇总RR 1.31,95%CI 1.14-1.51),有心血管病史者风险亦升高(汇总RR 1.31,95%CI 1.11-1.56)。作者指出残留混杂可能解释该发现,需进一步大型研究确认。
要点
- 主分析3项中等偏倚风险研究显示,地加瑞克较GnRH激动剂与MACE风险升高相关(汇总RR 1.31,95%CI 1.14-1.51)。
- 有心血管病史患者中2项研究显示风险升高(汇总RR 1.31,95%CI 1.11-1.56)。
- 无心血管病史患者中1项研究显示风险未达统计学显著(RR 1.15,95%CI 0.83-1.59)。
核心结论
- 真实世界证据研究提示,与GnRH激动剂相比,地加瑞克与MACE风险轻度升高相关,尤其在有心血管病史的患者中。
- 作者指出,因地加瑞克用于高危患者所致的残留混杂可能解释上述发现。
- 作者认为需要更多具有肿瘤特征和心血管危险因素详细数据的大型研究来确认这些发现。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library、Scopus和Web of Science(2008-2023年)。
- 纳入比较GnRH拮抗剂与GnRH激动剂心血管结局风险的真实世界证据研究。
- 共纳入10项研究,采用ROBINS-I工具评估偏倚风险,使用随机效应模型对低或中等偏倚风险研究的效应估计进行Meta分析。
主要发现
- 10项纳入研究中,4项为中等偏倚风险,6项为严重偏倚风险。
- 主分析中3项中等偏倚风险研究显示,地加瑞克与MACE风险升高相关(汇总RR 1.31,95%CI 1.14-1.51)。
- 有心血管病史患者中2项研究显示风险升高(汇总RR 1.31,95%CI 1.11-1.56)。
- 无心血管病史患者中1项研究显示风险未达统计学显著(RR 1.15,95%CI 0.83-1.59)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 10项纳入研究中6项为严重偏倚风险。
- 因地加瑞克用于高危患者所致的残留混杂可能解释所观察到的风险升高。
- 作者指出需要更多具有肿瘤特征和心血管危险因素详细数据的大型研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Gonadotropin-releasing hormone (GnRH) antagonists and agonists are cornerstone treatments in prostate cancer. However, evidence regarding the comparative cardiovascular safety of these drugs from clinical trials is inconclusive. The objective of this study was to systematically assess the risk of adverse cardiovascular events of GnRH antagonists compared with GnRH agonists across real-world evidence studies. METHODS: We conducted a systematic search of PubMed, Embase, Cochrane Library, Scopus, and Web of Science (2008-2023). We included real-world evidence studies comparing the risk of cardiovascular outcomes of GnRH antagonists with those of GnRH agonists among patients with prostate cancer. We conducted a meta-analysis of effect estimates across studies at a low or moderate risk of bias, assessed via the Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool, using random-effect models. KEY FINDINGS AND LIMITATIONS: Among ten included studies, four were classified as having a moderate and six as having a serious risk of bias. Across three studies at a moderate risk of bias in the primary analysis, degarelix was associated with an increased risk (pooled relative risk [RR]: 1.31, 95% confidence interval [CI]: 1.14-1.51) of major adverse cardiovascular events (MACEs). An augmented risk was observed in two studies among patients with a history of cardiovascular disease (pooled RR: 1.31, 95% CI: 1.11-1.56) compared with one study among patients without a history of cardiovascular disease (RR: 1.15, 95% CI: 0.83-1.59). CONCLUSIONS AND CLINICAL IMPLICATIONS: Real-world evidence studies indicate that degarelix, compared with GnRH agonists, is associated with a modest increased risk of MACEs, particularly among patients with a history of cardiovascular disease. However, residual confounding due to the treatment of high-risk patients with degarelix may account for these findings. Additional large studies with detailed data on tumor characteristics and cardiovascular risk factors are needed to confirm these findings. PATIENT SUMMARY: In this systematic evaluation of evidence among patients diagnosed with prostate cancer in routine care, degarelix was associated with higher cardiovascular adverse outcomes than gonadotropin-releasing hormone agonists.
引用
- Patel S, Zhu K, Dave CV, et al. Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies. Eur Urol Oncol. 2024. PMID: 39343637. doi:10.1016/j.euo.2024.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。